Lose 24% of weight in an average of 48 weeks! Retatrutide sets an astonishing record

    A mid-term study by Eli Lilly showed that an experimental drug called Retarutide at its highest dose helped obese patients lose an average of 24% of their weight within 48 weeks, which is the largest weight loss effect seen so far.

    Researchers reported in a study funded by Lilly that this drug called Retaglutide has similar side effects (mainly gastrointestinal side effects) to other approved drugs, including Ozempic, Wegovy, and Mounjaro. The study was funded by Lilly and published Monday in the New England Journal of Medicine. The results were also presented at the meeting of the American diabetes Association in San Diego.

These drugs mimic gut hormones to suppress appetite and slow gastric emptying, and are administered once a week. The pill version is also under development.

    Novo Nordisk Ozempic is approved for the treatment of type 2 diabetes, while Wegovy is approved for weight loss. They only imitate a hormone called GLP-1, and show up to 15% weight loss effect in the experiment. Mounjaro of Eli Lilly has been approved to treat type 2 diabetes and is waiting for FDA approval for weight loss. The drug targeting GLP-1 and a hormone called GIP has achieved 21% to 23% weight loss effect.

    Retaglutide has added a third target, glucagon, and is therefore known as the "triple G". In this mid-term trial, Lilly recruited approximately 340 obese adults with a body mass index of at least 30. The trial also included approximately 4% of overweight patients with a BMI between 27 and 30.

In addition to the average weight loss of 24% at the highest dose in the experiment (approximately 58 pounds over 11 months), a quarter of the patients who took this dose lost at least 30% of their weight.

  Buy Retarutide online clike here. https://www.goodpeptides.com/product/Retatrutide.html